Helmholtz Gemeinschaft


Different impact of gadopentetate and gadobutrol on inflammation-promoted retention and toxicity of gadolinium within the mouse brain

PDF (Original Paper) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
PDF (Supplemental Data) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader

Item Type:Article
Title:Different impact of gadopentetate and gadobutrol on inflammation-promoted retention and toxicity of gadolinium within the mouse brain
Creators Name:Anderhalten, L. and Silva, R.V. and Morr, A. and Wang, S. and Smorodchenko, A. and Saatz, J. and Traub, H. and Mueller, S. and Boehm-Sturm, P. and Rodriguez-Sillke, Y. and Kunkel, D. and Hahndorf, J. and Paul, F. and Taupitz, M. and Sack, I. and Infante-Duarte, C.
Abstract:OBJECTIVES: Using a murine model of multiple sclerosis, we previously showed that repeated administration of gadopentetate dimeglumine led to retention of gadolinium (Gd) within cerebellar structures and that this process was enhanced with inflammation. This study aimed to compare the kinetics and retention profiles of Gd in inflamed and healthy brains after application of the macrocyclic Gd-based contrast agent (GBCA) gadobutrol or the linear GBCA gadopentetate. Moreover, potential Gd-induced neurotoxicity was investigated in living hippocampal slices ex vivo. MATERIALS AND METHODS: Mice at peak of experimental autoimmune encephalomyelitis (EAE; n = 29) and healthy control mice (HC; n = 24) were exposed to a cumulative dose of 20 mmol/kg bodyweight of either gadopentetate dimeglumine or gadobutrol (8 injections of 2.5 mmol/kg over 10 days). Magnetic resonance imaging (7 T) was performed at baseline as well as at day 1, 10, and 40 post final injection (pfi) of GBCAs. Mice were sacrificed after magnetic resonance imaging and brain and blood Gd content was assessed by laser ablation-inductively coupled plasma (ICP)-mass spectrometry (MS) and ICP-MS, respectively. In addition, using chronic organotypic hippocampal slice cultures, Gd-induced neurotoxicity was addressed in living brain tissue ex vivo, both under control or inflammatory (tumor necrosis factor a [TNF-a] at 50 ng/µL) conditions. RESULTS: Neuroinflammation promoted a significant decrease in T1 relaxation times after multiple injections of both GBCAs as shown by quantitative T1 mapping of EAE brains compared with HC. This corresponded to higher Gd retention within the EAE brains at 1, 10, and 40 days pfi as determined by laser ablation-ICP-MS. In inflamed cerebellum, in particular in the deep cerebellar nuclei (CN), elevated Gd retention was observed until day 40 after last gadopentetate application (CN: EAE vs HC, 55.06 ± 0.16 µM vs 30.44 ± 4.43 µM). In contrast, gadobutrol application led to a rather diffuse Gd content in the inflamed brains, which strongly diminished until day 40 (CN: EAE vs HC, 0.38 ± 0.08 µM vs 0.17 ± 0.03 µM). The analysis of cytotoxic effects of both GBCAs using living brain tissue revealed an elevated cell death rate after incubation with gadopentetate but not gadobutrol at 50 mM. The cytotoxic effect due to gadopentetate increased in the presence of the inflammatory mediator TNF-a (with vs without TNF-a, 3.15% ± 1.18% vs 2.17% ± 1.14%; P = 0.0345). CONCLUSIONS: In the EAE model, neuroinflammation promoted increased Gd retention in the brain for both GBCAs. Whereas in the inflamed brains, efficient clearance of macrocyclic gadobutrol during the investigated time period was observed, the Gd retention after application of linear gadopentetate persisted over the entire observational period. Gadopentetate but not gadubutrol appeared to be neurotoxic in an ex vivo paradigm of neuronal inflammation.
Keywords:Cerebellar Nuclei, Experimental Autoimmune Encephalomyelitis, Gadolinium-Based Contrast Agents, Gadolinium Retention, Gadolinium-Induced, Toxicity, Imaging Mass Cytometry, Laser Ablation Inductively Coupled Plasma Mass, Spectrometry, Magnetic Resonance Imaging, Multiple Sclerosis, Neuroinflammation, Animals, Mice
Source:Investigative Radiology
Publisher:Lippincott Williams & Wilkins
Page Range:677-688
Date:1 October 2022
Official Publication:https://doi.org/10.1097/rli.0000000000000884
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library